Dr. Reddy’s, a global pharmaceutical company, has announced the completion of a definitive agreement with Johnson & Johnson to acquire STUGERON and its associated brands, STUGERON FORTE and STUGERON PLUS, across 18 markets in the Asia-Pacific (APAC) and Europe, Middle East and Africa (EMEA) regions. India and Vietnam will serve as the key markets for this acquisition.

STUGERON, which contains Cinnarizine—an antihistamine used in the treatment of vestibular disturbances and vertigo—already holds the leading position in India’s Cinnarizine represented pharmaceutical market and ranks second in the wider anti-vertigo extended represented pharmaceutical market. The acquisition provides Dr. Reddy’s with a significant opportunity to strengthen its presence in the anti-vertigo therapeutic space while further enhancing its Central Nervous System (CNS) portfolio.

Through this transaction, Dr. Reddy’s gains full rights to the STUGERON brand and its related portfolio across the identified markets. Operations will be transitioned gradually to ensure a smooth integration into Dr. Reddy’s existing business framework.

M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “The acquisition of STUGERON marks another step forward in our strategy to strengthen our CNS portfolio and broaden our footprint in the anti-vertigo segment. Leveraging our strong market access, we aim to expand the reach of STUGERON and its products across 18 key markets, including India and Vietnam. This aligns with our long-term commitment to enhancing patient access and progressing towards our goal of reaching more than 1.5 billion patients by 2030.”